Identification of Novel Biomarkers MCM2 and GINS2 for Cervical Cancer

Lei Chu1, Jie Yang2, Zhenshi Chen2, Xiajun Zhang1, Weidong Wu3*, Shaoru Zhang2 and Lihui Wang2*

1Clinical Laboratory, Danyang People’s Hospital of Jiangsu Province, Danyang Hospital Affliated to Nantong University, Jiangsu, China

2Central Laboratory, Danyang People’s Hospital of Jiangsu Province, Danyang Hospital Affliated to Nantong University, Jiangsu, China

3Anesthesiology Department, Danyang People’s Hospital of Jiangsu Province, Danyang Hospital Affliated to Nantong University, Jiangsu, China

Lei Chu, Jie Yang and Zhenshi Chen are the co-first authors.

ABSTRACT

Cervical cancer (CC) is the most common malignant tumor in women, and its prognosis is poor. The key genes and pathways of CC need to be further discovered. GEO2R was used to identify differentially expressed genes (DEG), GO and KEGG enrichment were analyzed by DAVID. Then, the PPI network is constructed with strings. The HUB gene and module of DEGS were obtained by Cytoscape. Finally, GEPIA also analyzed the differential expression and survival of key genes. 234 DEG were extracted from GSE9750. The uterus is the fourth organ highlighted in the concentrated analysis. The functional changes of DEGS are mainly related to cell cycle progression, cell cycle, helicase activity, DNA helicase activity, exosome and p53 signal pathway. In addition, five HUB genes and one key module were identified. Survival analysis showed that MCM2 and GINS2 were significantly correlated with overall survival. Expression analysis showed that MCM2 and GINS2 were highly expressed in cancer tissues, but low in normal tissues, which was consistent with the results of GEO analysis. Correlation analysis showed that there was a significant positive correlation between MCM2 and GINS2. This study suggests that MCM2 and GINS2 may be new biomarkers to predict the prognosis of CC.

Article Information

Received 16 November 2021

Revised 25 April 2022

Accepted 11 May 2022

Available online 30 March 2023

(early access)

Published 11 June 2024

Authors’ Contribution

LC project development and manuscript writing. JY project development and manuscript writing. ZC project development and manuscript writing. XZ and WW data collection. SZ methodology. LW data analysis and manuscript editing. Final approval of manuscript: All authors.

Key words

GINS2, MCM2, Cervical cancer, Prognosis, Differentially expressed genes

DOI: https://dx.doi.org/10.17582/journal.pjz/20211116011144

* Corresponding author: njuwanglihui@163.com

0030-9923/2024/0004-1781 $ 9.00/0

Copyright 2024 by the authors. Licensee Zoological Society of Pakistan.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Introduction

Cervical cancer (CC) is a common gynecological malignant tumor, it is the fourth leading cause of cancer-related death in women all over the world and ranks eighth among the most common cancers (Cosper et al., 2020). In recent decades, the incidence of CC in young women is on the rise (Lin et al., 2019). There were an estimated 527,600 new cases and 265,700 deaths worldwide in 2012. The global death toll in 2018 was 311,000. Although the morbidity and mortality of CC have decreased due to the improvement of diagnosis and treatment in recent years, the prognosis of secondary metastatic cancer and tumor recurrence is very poor (Nambaru et al., 2009).

Although human papillomavirus (HPV) is a prerequisite for CC (Yuan et al., 2018), only a few women infected with the virus develop cancer (Huijsmans et al., 2016). Therefore, other risk factors should be considered as auxiliary factors leading to the progression of CC (Luyten et al., 2014). Abnormal regulatory genes play an important role in the occurrence and development of cervical squamous cell carcinoma (Li et al., 2017; Alifu et al., 2018). Many studies have identified the key genes in cervical squamous cell carcinoma and normal cervical tissues through gene expression profile technology, and a large number of differentially expressed genes (DEG) have been detected (Shah et al., 2020). However, DEGs reported in different studies varies greatly, and only part of them are consistently detected. Thus, it is urgent to find new and effective targets for anti-CC therapy.

In this study, we selected the following microarray dataset GSE9750 from the Gene Expression Omnibus (GEO) database to identify DEGs. DEGs was analyzed through Kyoto Encyclopedia of Genes and Genomes (KEGG). A protein-protein interaction (PPI) network was constructed to clarify the important relationship between DEGs and to find HUB genes. In addition, the differential expression and survival analysis of HUB genes were carried out on Gene Expression Profiling Interactive Analysis (GEPIA). The purpose of this study is to better understand the characteristics of the genes and signal transduction pathways related to CC through bioinformatics analysis.

Materials and Methods

Microarray data

The gene expression profiles of GSE9750 were downloaded from GEO database. GSE9750, which was based on GPL96 platform (Affymetrix Human Genome U133A Array). The GSE9750 dataset contained 33 tumor samples and 24 normal cervical samples.

Identification of DEGs

The online tool, GEO2R was applied to determine DEGs in normal cervical tissues and CC tissues. Adjusted P-values were used to reduce the false positive rate using the Benjamini and Hochberg false discovery rate method by default. Adjusted P≤0.05 and |log fold change (FC)|≥1.5 were set as cut-off values. A total of 234 DEGs were then identified, including 55 up-regulated and 179 down-regulated genes. Eventually, the top 5 genes were determined as hub genes ranked by the Degree method in cytoHubba, a plugin in Cytoscape 3.6.0 software.

GO and KEGG enrichment analysis

The database for annotation, visualization and integrated discovery is a public online bioinformatic database which helps to identify the most significant enriched functional genes and biological pathways. To further analyze the DEGs, GO and KEGG enrichment analyses were performed by using the DAVID. GO analysis was used to annotate biological process (BP), cytological component (CC), and molecular function (MF) of genes, and KEGG enrichment analysis was used to understand the relevant signaling pathways, p value < 0.05 was considered to be statistically significant.

PPI network and key module analysis

We constructed the protein–protein interaction network (PPI) of DEGs by using Search Tool for the Retrieval of Interacting Genes database based on the confidence scores. What’s more, we further visualized the PPI by Cytoscape. And the Molecular Complex Detection (MCODE) plugin in Cytoscape was used to filter the key modules in the network with degree cutoff = 2, node score cutoff = 0.2, k-core = 2, and max. depth = 100. The criteria were set as follows: MCODE scores >3 and number of nodes >4.

Key genes screening and analysis

The genes with degree ≥10 in the network were identified as key genes, Gene Expression Profiling Interactive Analysis (GEPAI) is an interactive web application for gene expression analysis. We visualized the expression of key genes in CC tissues and normal tissues by box plots in GEPIA, and the overall survival analysis and correlation analysis of key genes was also performed.

Result

Identification of DEGs

There were 33 CC tissues and 24 normal cervical tissue samples analysed in this study. Firstly, the GEO2R tool was employed to identify DEGs using the following cut-off values: Adjusted P≤0.05 and |logFC|≥1.5. As a result, a total of 234 DEGs were identified, including 55 up-regulated and 179 down-regulated genes (Fig. 1).

 

GO enrichment and KEGG pathway enrichment

We uploaded all DEGs to DAVID to identify overrepresented GO categories and KEGG pathways. The enriched results of tissue expression were revealed, the screened DEGs were enriched in tissues including Foreskin, Keratinocyte, Skin, Tongue, Esophagus, Bone marrow, Plasma, Uterus, Placenta and Epithelium (Table I). In the GO analysis, the screened DEGs mainly participate

 

Table I. Enrichment analysis of 234 differentially expressed genes in different tissues.

Category	Term	Count	%	P-value	FDR
UP_TISSUE	Foreskin	6	3.14	1.84E-04	0.219073889
UP_TISSUE	Keratinocyte	8	4.19	4.55E-04	0.540274684
UP_TISSUE	Skin	33	17.3	0.002057593	2.424061768
UP_TISSUE	Tongue	10	5.24	0.026234963	27.14758832
UP_TISSUE	Esophagus	3	1.57	0.033587692	33.43796859
UP_TISSUE	Bone marrow	15	7.85	0.034025143	33.79604522
UP_TISSUE	Plasma	7	3.66	0.067794744	56.67257722
UP_TISSUE	Uterus	25	13.09	0.074480313	60.23314132
UP_TISSUE	Placenta	43	22.51	0.085638329	65.58380022
UP_TISSUE	Epithelium	35	18.32	0.092928299	68.71433346

 

in the biological process (BP) of epithelial cell differentiation, epidermis development, skin development, epidermal cell differentiation, mitotic cell cycle process, keratinocyte differentiation, epithelium development, cell cycle process, cell cycle and mitotic cell cycle. As for the molecular function (MF), DEGs mainly involved in serine-type peptidase activity, serine hydrolase activity, serine-type endopeptidase activity, structural molecule activity, helicase activity, DNA helicase activity and calcium ion binding. The cell component (CC) of DEGs includes extracellular region part, extracellular exosome, extracellular vesicle, extracellular organelle, membrane-bounded vesicle, extracellular region, cornified envelope and apical plasma membrane. In the KEGG pathway analysis found that DEGs significantly enriched in Gap junction, Estrogen signaling pathway and p53 signaling pathway (Table II).

 

PPI network construction and analysis

PPI network of 234 DEGs was constructed in STRING, the network visualized by Cytoscape. MOCD plug-in screened out one key modules, which were composed by up-regulated genes (Fig. 2). Red nodes represent up-regulated genes. Degree ≥ 10 as screening criteria, 5 key genes were screened to form key modules; Their names are shown in Table III.

 

 

Table II. GO and KEGG pathway enrichment analysis of DEGs.

Category	Term	Count	P value
Biological processes
GO:0030855	epithelial cell differentiation	28	3.93E-11
GO:0008544	epidermis development	21	5.41E-11
GO:0043588	skin development	19	5.81E-11
GO:0009913	epidermal cell differentiation	16	6.22E-10
GO:1903047	mitotic cell cycle process	32	3.38E-09
GO:0030216	keratinocyte differentiation	13	4.45E-09
GO:0060429	epithelium development	34	1.56E-08
GO:0022402	cell cycle process	39	1.82E-08
GO:0007049	cell cycle	44	2.06E-08
GO:0000278	mitotic cell cycle	32	2.40E-08
Cell component
GO:0044421	extracellular region part	80	2.97E-08
GO:0070062	extracellular exosome	64	6.07E-08
GO:1903561	extracellular vesicle	64	7.35E-08
GO:0043230	extracellular organelle	64	7.45E-08
GO:0031988	membrane-bounded vesicle	74	2.20E-07
GO:0005576	extracellular region	87	3.49E-07
GO:0001533	cornified envelope	8	1.01E-06
GO:0016324	apical plasma membrane	15	9.63E-06
Molecular function
GO:0008236	serine-type peptidase activity	12	2.35E-04
GO:0017171	serine hydrolase activity	12	2.57E-04
GO:0004252	serine-type endopeptidase activity	11	4.33E-04
GO:0005198	structural molecule activity	20	7.30E-04
GO:0004386	helicase activity	8	0.001640
GO:0003678	DNA helicase activity	5	0.003037
GO:0005509	calcium ion binding	17	0.004460
KEGG pathway
hsa04540	Gap junction	5	0.018922
hsa04915	Estrogen signaling pathway	5	0.027773
hsa04115	p53 signaling pathway	4	0.04265

 

Key gene analysis

All aforementioned 5 hub genes were analyzed using the prognostic values of OS and DFS via the GEPIA website. GINS2 and MCM2 were significantly associated with OS (log-rank P= 0.035 and 0.0092 (Fig. 3A and B). The analysis of these two genes revealed that low expression levels led to better survival status. The other hub genes did not exhibit statistical significance. The genes GINS2 and MCM2 were then subjected to further analysis. Expression levels of these two genes are displayed in Figure 4A, B. Both GINS2 and MCM2 presented high expression levels in CC tissues, but exhibited low expression levels in normal cervical tissues. In addition, Pearson correlation analyses between the genes are presented in Figure 4C. Results revealed that GINS2 was positively correlated with MCM2(R=0.52, P=0).

 

Table III. Functional roles of 5 key genes with degree ≥10.

Gene symbol	Degree	Full name
MCM2	26	minichromosome maintenance complex component 2
MCM5	26	minichromosome maintenance complex component 5
GINS1	24	GINS complex subunit 1
GINS2	24	GINS complex subunit 2
MCM6	24	minichromosome maintenance complex component 6

 

Discussion

In the study, we investigated the potential prognostic association between CC and DEGS in GSE9750. The results showed that there were 234 DEGs in 24 normal cervical tissues and 33 CC tissues, including 55 up-regulated genes and 179 down-regulated genes. Both up-regulated and down-regulated genes were enriched in multiple organs. Notably, the uterus was the fourth organ highlighted in the enrichment analysis. Five hub genes were screened and one module was identified. GINS2 and MCM2 genes have potential prognostic value in patients with CC.

Although the morbidity and mortality of CC have declined in recent years due to improvements in diagnosis and treatment, the clinical outcome of advanced diseases is still very dim (Cuschieri et al., 2014). In addition, lymph node metastasis can lead to higher mortality and recurrence rates (Liu et al., 2020), even in patients with early CC (Li et al., 2016), and exact lymph node status information is essential for tailored adjuvant therapy (Zhang et al., 2014). However, so far, there are no sensitive biomarkers that specifically reflect the indications of lymph node metastasis, as well as the early detection and prognosis of CC.

GINS complex 2 (GINS2), also known as PSF2, encodes a protein with a molecular weight of about 21 kDa (Ye et al., 2019). GINS2 belongs to the GINS complex family, which also includes GINS2, GINS3 and GINS4. GINS complex plays an important role in initiating DNA replication and cell cycle (Chi et al., 2020). The GINS family is involved in the maintenance of micro chromosomes (MCM) 2-mel-7 complex and cdc45 maintain stable interaction, which can correctly establish and maintain DNA replication bifurcations (Peng et al., 2016). In addition, the GINS component may play a role in cell division or, more accurately, in chromosome segregation. Ouyang et al. (2017) found that GINS2 gene knockout inhibits the proliferation, tumorigenicity, migration and invasion of CC cells (Ouyang et al., 2017). This is consistent with the results of this study, high expression of GINS2 in CC, low expression in normal cervical tissues, therefore, low expression of GINS2 leads to better survival. These results suggest that GINS2 may be a new index to identify high-risk patients and may be used as a clinical biomarker to predict the prognosis of patients with early CC.

In addition, GINS2 is reported to be associated with several other types of cancer (Yan et al., 2018). Such as, genome-wide gene expression profile analysis shows that GINS2 is highly expressed in lung cancer (Liu et al., 2019). Zheng et al., (2014) believe that GINS2 is related to the invasiveness of breast cancer and speculate that it is related to lung metastasis (Zheng et al., 2014). Besides, the increased expression of GINS2 can promote the proliferation of leukemic cells and reduce the sensitivity of leukemic cells to apoptosis (Gao et al., 2013). These findings suggest that GINS2 plays an important role in cancer progression.

A series of events during HPV infection can cause host cells to experience an unplanned cell cycle (Hernadi et al., 2003). This phenomenon leads to cell division out of control, promotes cell proliferation, and then leads to cancer. In HPV-related CC, cancer cells up-regulate specific genes that control several steps of DNA replication. Microchromosome maintenance complex (MCM) is an essential protein in DNA replication and cell division. Kaur et al. (2019) showed that the expression of MCM gene was up-regulated during the carcinogenesis of CC, which once again proved that MCM is a proliferation marker in the DNA replication pathway, which makes dysplasia and cancer cell proliferation more and more out of control (Kaur et al., 2019). MCMs is a candidate marker of cell proliferation. The increase of MCMs level indicates the proliferation of malignant cells. This is consistent with the results of this study, the expression of MCM2 is high in CC tissue and low in normal cervical tissue.

In addition, there is some evidence that MCM can predict tumor progression. Studies have shown that MCM protein is highly expressed in several other types of cancers (Pruitt et al., 2007), such as lung cancer (Cheung et al., 2017), breast cancer (Yousef et al., 2017; Issac et al., 2019), colon cancer (Burger, 2009), and other cancers (Deng et al., 2019) MCM protein may also be used as a potential diagnostic or prognostic marker for them.

CONCLUSION

In this study, 234 DEGs and 5 hub genes were identified in CC patients. Only MCM2 and GINS2 genes have prognostic value in patients with CC. This study suggests that MCM2 and GINS2 may be potential prognostic biomarkers of CC. In addition, MCM2 and GINS2 may play a carcinogenic role in cervical tumors. These genes may play a role through cell cycle process, cell cycle and helicase activity, DNA helicase activity, exosome and p53 signal pathway. Further research is needed to explore the functional role of these genes, especially in metastasis and cancer progression, in order to guide the clinical direction. The purpose of this study is to better understand the characteristics of cervical cancer-related genes and signal transduction pathways by means of bioinformatics, and to provide further research ideas for discovering new pathogenesis, more prognostic factors and potential therapeutic targets of CC.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (31700444), Social Development Guide Project of Zhenjiang (FZ2019006), Key research and development Social Development Project of Zhenjiang (SH2021064).

Statement of conflict of interest

The authors have declared no conflict of interest.

References

Alifu, M., Fan, P., Kuerban, G., Yao, X., Peng, Y., Dong, T. and Wang, R., 2018. Frequency distribution of hla alleles and haplotypes in uyghur women with advanced squamous cell cervical cancer and relation to hpv status and clinical outcome. Arch. Gynecol. Obstet., 297: 757-766. https://doi.org/10.1007/s00404-018-4662-3

Burger, M., 2009. Mcm2 and mcm5 as prognostic markers in colon cancer: A worthwhile approach. Dig. Dis. Sci., 54: 197-198. https://doi.org/10.1007/s10620-008-0416-6

Cheung, C.H.Y., Hsu, C.L., Chen, K.P., Chong, S.T., Wu, C.H., Huang, H.C., and Juan, H.F., 2017. Mcm2-regulated functional networks in lung cancer by multi-dimensional proteomic approach. Sci. Rep., 7: 13302. https://doi.org/10.1038/s41598-017-13440-x

Chi, F., Wang, Z., Li, Y., and Chang, N., 2020. Knockdown of gins2 inhibits proliferation and promotes apoptosis through the p53/gadd45a pathway in non-small cell lung cancer. Biosci. Rep., https://doi.org/10.1042/BSR20193949

Cosper, P.F., McNair, C., Gonzalez, I., Wong, N., Knudsen, K.E., Chen, J.J., Markovina, S., Schwarz, J.K., Grigsby, P.W., and Wang, X., 2020. Decreased local immune response and retained hpv gene expression during chemoradiotherapy are associated with treatment resistance and death from cervical cancer. Int. J. Cancer, 146: 2047-2058. https://doi.org/10.1002/ijc.32793

Cuschieri, K., Brewster, D.H., Graham, C., Nicoll, S., Williams, A.R., Murray, G.I., Millan, D., Johannessen, I., Hardie, A., and Cubie, H.A., 2014. Influence of hpv type on prognosis in patients diagnosed with invasive cervical cancer. Int. J. Cancer, 135: 2721-2726. https://doi.org/10.1002/ijc.28902

Deng, M., Sun, J., Xie, S., Zhen, H., Wang, Y., Zhong, A., Zhang, H., Lu, R. and Guo, L., 2019. Inhibition of mcm2 enhances the sensitivity of ovarian cancer cell to carboplatin. Mol. Med. Rep., 20: 2258-2266. https://doi.org/10.3892/mmr.2019.10477

Gao, Y., Wang, S., Liu, B., and Zhong, L., 2013. Roles of gins2 in k562 human chronic myelogenous leukemia and nb4 acute promyelocytic leukemia cells. Int. J. mol. Med., 31: 1402-1410. https://doi.org/10.3892/ijmm.2013.1339

Hernadi, Z., Szarka, K., Sapy, T., Krasznai, Z., Veress, G., and Poka, R., 2003. The prognostic significance of hpv-16 genome status of the lymph nodes, the integration status and p53 genotype in hpv-16 positive cervical cancer: A long term follow up. BJOG Int. J. Obstet. Gynaecol., 110: 205-209. https://doi.org/10.1046/j.1471-0528.2003.01516.x

Huijsmans, C.J., Geurts-Giele, W.R., Leeijen, C., Hazenberg, H.L., van Beek, J., de Wild, C., van der Linden, J.C., and van den Brule, A.J., 2016. Hpv prevalence in the dutch cervical cancer screening population (dusc study): Hpv testing using automated hc2, cobas and aptima workflows. BMC Cancer, 16: 922. https://doi.org/10.1186/s12885-016-2961-2

Issac, M.S.M., Yousef, E., Tahir, M.R. and Gaboury, L.A., 2019. Mcm2, mcm4, and mcm6 in breast cancer: Clinical utility in diagnosis and prognosis. Neoplasia, 21: 1015-1035. https://doi.org/10.1016/j.neo.2019.07.011

Kaur, G., Balasubramaniam, S.D., Lee, Y.J., Balakrishnan, V., and Oon, C.E., 2019. Minichromosome maintenance complex (mcm) genes profiling and mcm2 protein expression in cervical cancer development. Asian Pac. J. Cancer Prev., 20: 3043-3049. https://doi.org/10.31557/APJCP.2019.20.10.3043

Li, Y.P., Zhang, L., Zou, Y.L., and Yu, Y., 2017. Association between fgfr4 gene polymorphism and high-risk hpv infection cervical cancer. Asian Pac. J. trop. Med., 10: 680-684. https://doi.org/10.1016/j.apjtm.2017.07.008

Li, Z., Yang, Y., Gao, Y., Wu, X., Yang, X., Zhu, Y., Yang, H., Wu, L., Yang, C., and Song, L., 2016. Elevated expression of flotillin-1 is associated with lymph node metastasis and poor prognosis in early-stage cervical cancer. Am. J. Cancer Res., 6: 38-50.

Lin, G., Yang, L.Y., Lin, Y.C., Huang, Y.T., Liu, F.Y., Wang, C.C., Lu, H.Y., Chiang, H.J., Chen, Y.R., Wu, R.C., Ng, K.K., Hong, J.H., Yen, T.C. and Lai, C.H., 2019. Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and hpv genotyping for stage ib-iv cervical cancer patients following chemoradiotherapy. Eur. Radiol., 29: 556-565. https://doi.org/10.1007/s00330-018-5651-4

Liu, J., Li, S., Lin, L., Jiang, Y., Wan, Y., Zhou, S. and Cheng, W., 2020. Co-expression network analysis identified atypical chemokine receptor 1 (ackr1) association with lymph node metastasis and prognosis in cervical cancer. Cancer Biomark. A Dis. Markers, 27: 213-223. https://doi.org/10.3233/CBM-190533

Liu, X., Sun, L., Zhang, S., Zhang, S., and Li, W., 2019. Gins2 facilitates epithelial-to-mesenchymal transition in non-small-cell lung cancer through modulating pi3k/akt and mek/erk signaling. J. cell. Physiol., 235: 7747-7756. https://doi.org/10.1002/jcp.29381

Luyten, A., Buttmann-Schweiger, N., Luyten, K., Mauritz, C., Reinecke-Luthge, A., Pietralla, M., Meijer, C.J. and Petry, K.U., 2014. Early detection of cin3 and cervical cancer during long-term follow-up using hpv/pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int. J. Cancer, 135: 1408-1416. https://doi.org/10.1002/ijc.28783

Nambaru, L., Meenakumari, B., Swaminathan, R., and Rajkumar, T., 2009. Prognostic significance of hpv physical status and integration sites in cervical cancer. Asian Pac. J. Cancer Prev., 10: 355-360.

Ouyang, F., Liu, J., Xia, M., Lin, C., Wu, X., Ye, L., Song, L., Li, J., Wang, J., Guo, P., and He, M., 2017. Gins2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer. Oncol. Rep., 37: 2652-2662. https://doi.org/10.3892/or.2017.5573

Peng, L., Song, Z., Chen, D., Linghu, R., Wang, Y., Zhang, X., Kou, X., Yang, J., and Jiao, S., 2016. Gins2 regulates matrix metallopeptidase 9 expression and cancer stem cell property in human triple negative breast cancer. Biomed. Pharmacother. Biomed. Pharmacother., 84: 1568-1574. https://doi.org/10.1016/j.biopha.2016.10.032

Pruitt, S.C., Bailey, K.J., and Freeland, A., 2007. Reduced mcm2 expression results in severe stem/progenitor cell deficiency and cancer. Stem Cells, 25: 3121-3132. https://doi.org/10.1634/stemcells.2007-0483

Shah, U.J., Nasiruddin, M., Dar, S.A., Khan, M.K.A., Akhter, M.R., Singh, N., Rabaan, A.A., and Haque, S., 2020. Emerging biomarkers and clinical significance of hpv genotyping in prevention and management of cervical cancer. Microb. Pathog., 143: 104131. https://doi.org/10.1016/j.micpath.2020.104131

Yan, T., Liang, W., Jiang, E., Ye, A., Wu, Q., and Xi, M., 2018. Gins2 regulates cell proliferation and apoptosis in human epithelial ovarian cancer. Oncol. Lett., 16: 2591-2598. https://doi.org/10.3892/ol.2018.8944

Ye, Y., Song, Y.N., He, S.F., Zhuang, J.H., Wang, G.Y., and Xia, W., 2019. Gins2 promotes cell proliferation and inhibits cell apoptosis in thyroid cancer by regulating cited2 and loxl2. Cancer Gene Ther., 26: 103-113. https://doi.org/10.1038/s41417-018-0045-y

Yousef, E.M., Furrer, D., Laperriere, D.L., Tahir, M.R., Mader, S., Diorio, C., and Gaboury, L.A., 2017. Mcm2: An alternative to ki-67 for measuring breast cancer cell proliferation. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol., Inc., 30: 682-697. https://doi.org/10.1038/modpathol.2016.231

Yuan, Y., Min, S.J., Xu, D.Q., Shen, Y., Yan, H.Y., Wang, Y., Wang, W., and Tan, Y.J., 2018. Expressions of vegf and mir-21 in tumor tissues of cervical cancer patients with hpv infection and their relationships with prognosis. Eur. Rev. Med. Pharmacol. Sci., 22: 6274-6279.

Zhang, X., Zheng, Z., Yingji, S., Kim, H., Jin, R., Renshu, L., Lee, D.Y., Roh, M.R. and Yang, S., 2014. Downregulation of glutathione peroxidase 3 is associated with lymph node metastasis and prognosis in cervical cancer. Oncol. Rep., 31: 2587-2592. https://doi.org/10.3892/or.2014.3152

Zheng, M., Zhou, Y., Yang, X., Tang, J., Wei, D., Zhang, Y., Jiang, J.L., Chen, Z.N. and Zhu, P., 2014. High gins2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients. Breast Cancer Res. Treat., 148: 423-436. https://doi.org/10.1007/s10549-014-3172-7